Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Ventyx Biosciences (Nasdaq: VTYX) announced a $27 million strategic investment from Sanofi. Sanofi will purchase 70,601 shares of Ventyx's Series A non-voting convertible preferred stock at $3.8243 per share, convertible into 100 shares of common stock each. The transaction is expected to close on September 23, 2024.
As part of the deal, Sanofi receives an exclusive right of first negotiation for Ventyx's CNS-penetrant NLRP3 inhibitor VTX3232. Ventyx CEO Raju Mohan expressed optimism about the investment, highlighting Sanofi's leadership in immunological and inflammatory diseases. The company expects data from VTX3232's Phase 2a trial in early Parkinson's disease and Phase 2 trial in obesity with cardiometabolic risk factors in 2025.
The investment is expected to strengthen Ventyx's cash position, with current resources projected to fund operations into at least the second half of 2026.
Ventyx Biosciences (Nasdaq: VTYX) ha annunciato un investimento strategico di 27 milioni di dollari da parte di Sanofi. Sanofi acquisterà 70.601 azioni della serie A di Ventyx, stock preferenziale non votante convertibile, a 3,8243 dollari per azione, convertibile in 100 azioni di comune. Si prevede che la transazione si chiuda il 23 settembre 2024.
Come parte dell'accordo, Sanofi riceve un diritto esclusivo di prima negoziazione per l'inibitore NLRP3 penetrante nel sistema nervoso centrale di Ventyx, VTX3232. Il CEO di Ventyx, Raju Mohan, ha espresso ottimismo riguardo all'investimento, evidenziando la leadership di Sanofi nelle malattie immunologiche e infiammatorie. L'azienda si aspetta dati dal trial di Fase 2a di VTX3232 nella malattia di Parkinson precoce e dal trial di Fase 2 sull'obesità con fattori di rischio cardiometabolici nel 2025.
L'investimento dovrebbe rafforzare la posizione di cassa di Ventyx, con risorse attuali previste per finanziare le operazioni almeno fino alla seconda metà del 2026.
Ventyx Biosciences (Nasdaq: VTYX) anunció una inversión estratégica de 27 millones de dólares por parte de Sanofi. Sanofi comprará 70,601 acciones de la serie A de acciones preferentes convertibles no votantes de Ventyx a 3.8243 dólares por acción, convertible en 100 acciones comunes cada una. Se espera que la transacción se cierre el 23 de septiembre de 2024.
Como parte del acuerdo, Sanofi recibe un derecho exclusivo de primera negociación para el inhibidor NLRP3 penetrante en el SNC de Ventyx, VTX3232. El CEO de Ventyx, Raju Mohan, expresó optimismo sobre la inversión, destacando el liderazgo de Sanofi en enfermedades inmunológicas e inflamatorias. La compañía espera datos del ensayo de Fase 2a de VTX3232 en la enfermedad de Parkinson en sus primeras etapas y del ensayo de Fase 2 en obesidad con factores de riesgo cardiometabólicos en 2025.
Se espera que la inversión fortalezca la posición de caja de Ventyx, con recursos actuales proyectados para financiar operaciones al menos hasta la segunda mitad de 2026.
벤트릭스 바이오사이언스(Ventyx Biosciences, Nasdaq: VTYX)는 사노피(Sanofi)로부터 2천7백만 달러의 전략적 투자를 발표했습니다. 사노피는 벤트릭스의 비의결권 전환 우선주 시리즈 A 주식 70,601주를 주당 3.8243달러에 구매하며, 이는 각각 100주의 보통주로 전환될 수 있습니다. 거래는 2024년 9월 23일에 완료될 것으로 예상됩니다.
합의의 일환으로, 사노피는 벤트릭스의 CNS 침투성 NLRP3 저해제 VTX3232에 대한 독점적인 우선 협상권을 획득합니다. 벤트릭스의 CEO 라주 모한(Raju Mohan)은 이 투자의 낙관론을 표현하며, 면역학 및 염증질환에서 사노피의 리더십을 강조했습니다. 회사는 VTX3232의 2a상 시험에서 조기 파킨슨병과 2상 시험에서 심혈관 대사 위험 요소가 있는 비만에 관한 데이터를 2025년 초에 기대하고 있습니다.
이 투자는 벤트릭스의 현금 유동성을 강화할 것으로 예상되며, 현재 자원은 최소 2026년 하반기까지 운영 자금을 지원할 것으로 예상됩니다.
Ventyx Biosciences (Nasdaq: VTYX) a annoncé un investissement stratégique de 27 millions de dollars de Sanofi. Sanofi achètera 70 601 actions des actions préférentielles convertibles de série A non votantes de Ventyx au prix de 3,8243 dollars par action, convertibles en 100 actions ordinaires chacune. La transaction devrait être finalisée le 23 septembre 2024.
Dans le cadre du contrat, Sanofi obtient un droit exclusif de première négociation pour l'inhibiteur NLRP3 pénétrant le SNC de Ventyx, VTX3232. Le PDG de Ventyx, Raju Mohan, a exprimé son optimisme concernant l'investissement, soulignant le leadership de Sanofi dans les maladies immunologiques et inflammatoires. L'entreprise s'attend à des données sur l'essai de Phase 2a de VTX3232 dans les premiers stades de la maladie de Parkinson et sur l'essai de Phase 2 sur l'obésité avec des facteurs de risque cardiométaboliques en 2025.
L'investissement devrait renforcer la position de trésorerie de Ventyx, les ressources actuelles étant prévues pour financer les opérations au moins jusqu'à la deuxième moitié de 2026.
Ventyx Biosciences (Nasdaq: VTYX) gab eine strategische Investition von 27 Millionen US-Dollar durch Sanofi bekannt. Sanofi wird 70.601 Aktien der nicht stimmberechtigten wandelbaren Vorzugsaktien der Serie A von Ventyx zu einem Preis von 3,8243 US-Dollar pro Aktie erwerben, die in jeweils 100 Stammaktien umwandelbar sind. Es wird erwartet, dass die Transaktion am 23. September 2024 abgeschlossen wird.
Im Rahmen des Deals erhält Sanofi ein exklusives Recht auf erste Verhandlung für Ventyx’ CNS-penetranten NLRP3-Inhibitor VTX3232. Der CEO von Ventyx, Raju Mohan, äußerte Optimismus hinsichtlich der Investition und hob Sanofis Führungsrolle bei immunologischen und entzündlichen Erkrankungen hervor. Das Unternehmen erwartet Daten aus der Phase-2a-Studie von VTX3232 bei früher Parkinson-Krankheit und der Phase-2-Studie bei Fettleibigkeit mit kardiometabolischen Risikofaktoren im Jahr 2025.
Die Investition soll die Liquidität von Ventyx stärken, wobei die aktuellen Ressourcen voraussichtlich die Operationen mindestens bis in die zweite Hälfte des Jahres 2026 finanzieren werden.
- Strategic $27 million investment from Sanofi, a global leader in immunological and inflammatory diseases
- Exclusive right of first negotiation granted to Sanofi for VTX3232 program rights
- Strengthened cash position expected to fund operations into at least the second half of 2026
- Ongoing Phase 2a trial for VTX3232 in early Parkinson's disease
- Ongoing Phase 2 trial for VTX3232 in obesity with cardiometabolic risk factors
- None.
Insights
This strategic investment from Sanofi is a significant positive development for Ventyx Biosciences. The
The exclusive right of first negotiation granted to Sanofi for VTX3232 could potentially lead to a lucrative partnership or acquisition in the future, especially if the upcoming Phase 2 trials show promising results. This deal structure allows Ventyx to retain control while securing a potential commercialization partner.
Investors should closely monitor the Phase 2a trial results in Parkinson's disease and the Phase 2 trial in obesity, both expected in 2025. Positive outcomes could significantly increase Ventyx's valuation and Sanofi's interest in a larger deal.
Ventyx's VTX3232, a CNS-penetrant NLRP3 inhibitor, represents a promising approach to treating neuroinflammatory conditions. The NLRP3 inflammasome is a key driver of inflammation in various diseases and its inhibition in the central nervous system could potentially modify disease progression in conditions like Parkinson's.
The ongoing Phase 2a trial in early Parkinson's disease is particularly intriguing, as current treatments primarily address symptoms rather than underlying disease mechanisms. If VTX3232 demonstrates disease-modifying effects, it could revolutionize Parkinson's treatment.
Additionally, the Phase 2 trial in obesity with cardiometabolic risk factors highlights the broad potential of NLRP3 inhibition. Chronic inflammation plays a important role in obesity and related metabolic disorders and targeting this pathway could yield significant benefits.
Sanofi's investment validates the potential of this approach and could accelerate the development and potential commercialization of VTX3232.
Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a
“We are very pleased with this strategic investment from Sanofi,” said Raju Mohan, Chief Executive Officer. “Sanofi is a global leader in immunological and inflammatory diseases, and we believe this transaction is a recognition that VTX3232 could potentially offer a disease-modifying approach for the treatment of a number of neuroinflammatory conditions with high unmet medical need. We look forward to strengthening our relationship with Sanofi as the VTX3232 clinical programs progress, with data from the Phase 2a trial in patients with early Parkinson’s disease and data from the Phase 2 trial in subjects with obesity and additional cardiometabolic risk factors, both expected in 2025.”
In connection with the equity investment, the Company has agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 program rights.
The proceeds from the investment are expected to further strengthen the Company’s cash position, and current cash, cash equivalents and marketable securities, inclusive of the proceeds from the investment, are expected to be sufficient to fund planned operations into at least the second half of 2026.
About VTX3232
VTX3232 is an oral, selective, CNS-penetrant NLRP3 inhibitor with potential therapeutic utility for a range of neuroinflammatory and neurodegenerative conditions, including Parkinson’s disease, cardiometabolic disease, Alzheimer’s disease, and multiple sclerosis, among others. In the first quarter of this year, Ventyx announced results from a Phase 1 trial of VTX3232 in adult healthy volunteers where steady-state exposures achieved with once-daily doses of VTX3232 exceeded the interleukin-1β (IL-1β) IC90 in both plasma and cerebrospinal fluid over 24 hours. We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases. Current development plans for VTX3232 include a Phase 2a trial in patients with early Parkinson’s disease and a Phase 2 trial in subjects with obesity and additional cardiometabolic risk factors. Data from both trials are expected in 2025.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical needs with novel oral therapies that can shift inflammation and immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral immunology therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.
Forward-Looking Statements
Ventyx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Ventyx’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the potential for VTX3232 to offer a disease-modifying approach for the treatment of neuroinflammatory conditions with high unmet medical need; the impact of Sanofi’s strategic investment and Ventyx’s relationship with Sanofi; clinical progress regarding VTX3232, including the timing of data from the Phase 2a trial in patients with early Parkinson’s disease and data from the Phase 2 trial in subjects with obesity and additional cardiometabolic risk factors; the expected timeframe for funding Ventyx’s operating plan with current cash, cash equivalents and marketable securities, inclusive of the proceeds from Sanofi’s investment; the potential therapeutic utility of VTX3232 for a range of neuroinflammatory and neurodegenerative conditions, including Parkinson’s disease, cardiometabolic disease, Alzheimer’s disease, and multiple sclerosis, among others; the potential of VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases; Ventyx’s ability to address important unmet medical needs with novel oral therapies that can shift inflammation and immunology markets from injectable to oral drugs; and Ventyx’s positioning to become a leader in the development of oral immunology therapies for peripheral and neuroinflammatory diseases. The inclusion of forward-looking statements should not be regarded as a representation by Ventyx that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Ventyx’s business, including, without limitation: Ventyx’s relationship with Sanofi may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, delays in site activations and enrollment of clinical trials; the results of preclinical studies and clinical trials; early clinical trials not necessarily being predictive of future results; the ongoing contributions to scientific literature as pertains to the relationships between NLRP3, neuroinflammation and Parkinson’s disease; unexpected adverse side effects or inadequate efficacy of Ventyx’s product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Ventyx’s ability to obtain and maintain intellectual property protection for its product candidates; the use of capital resources by Ventyx sooner than expected; and other risks described in Ventyx’s prior press releases and Ventyx’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of Ventyx’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on August 8, 2024, and Ventyx’s subsequent filings with the SEC.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Ventyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
FAQ
What is the value of Sanofi's strategic investment in Ventyx Biosciences (VTYX)?
What rights does Sanofi receive in the deal with Ventyx Biosciences (VTYX)?
When are the results expected for VTX3232's clinical trials by Ventyx Biosciences (VTYX)?
How long is Ventyx Biosciences' (VTYX) cash runway following Sanofi's investment?
